Quest Diagnostics (DGX) Change in Receivables (2009 - 2026)

Quest Diagnostics has disclosed Change in Receivables across 18 years of filings, most recently posting $180.0 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at $180.0 million, up 78.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $185.0 million (up 218.97% YoY), and the FY2025 annual result was $106.0 million, up 49.3% from the prior year.
• Change in Receivables came in at $180.0 million for Q1 2026 at Quest Diagnostics, up from -$47.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $180.0 million in Q1 2026 to a low of -$84.0 million in Q4 2022.
• The 5-year median for Change in Receivables is -$1.0 million (2024), against an average of $7.4 million.
• Across the five-year window, Change in Receivables slumped 133.33% in 2022 and jumped 1500.0% in 2025, its largest moves.
• Quest Diagnostics' Change in Receivables stood at -$84.0 million in 2022, then grew by 15.48% to -$71.0 million in 2023, then increased by 2.82% to -$69.0 million in 2024, then surged by 31.88% to -$47.0 million in 2025, then jumped by 482.98% to $180.0 million in 2026.
• The last three Change in Receivables figures came in at $180.0 million (Q1 2026), -$47.0 million (Q4 2025), and $38.0 million (Q3 2025), per Business Quant data.